Home » Stocks » ACRX

AcelRx Pharmaceuticals, Inc. (ACRX)

Stock Price: $1.91 USD 0.00 (0.00%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 189.68M
Revenue (ttm) 5.15M
Net Income (ttm) -45.88M
Shares Out 87.91M
EPS (ttm) -0.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $1.91
Previous Close $1.91
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.90
Day's Range 1.81 - 1.92
Day's Volume 6,367,054
52-Week Range 0.76 - 2.35

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 3 days ago

The company announced the pricing of a public stock offering.

PRNewsWire - 4 days ago

REDWOOD CITY, Calif., Jan. 19, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

Zacks Investment Research - 1 week ago

Investors need to pay close attention to AcelRx (ACRX) stock based on the movements in the options market lately.

PRNewsWire - 1 month ago

REDWOOD CITY, Calif., Dec. 10, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovati...

PRNewsWire - 1 month ago

REDWOOD CITY, Calif., Dec. 9, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovativ...

PRNewsWire - 1 month ago

REDWOOD CITY, Calif., Dec. 4, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovativ...

Seeking Alpha - 2 months ago

Acelrx shares plummeted after the company released third quarter earnings. However, numbers were significantly up compared to any prior period.

PRNewsWire - 2 months ago

REDWOOD CITY, Calif., Nov. 6, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovativ...

Seeking Alpha - 2 months ago

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -42.86% and -77.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead ...

Zacks Investment Research - 2 months ago

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 3 months ago

AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 3 months ago

AcelRx (ACRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Zacks Investment Research - 3 months ago

Investors need to pay close attention to AcelRx (ACRX) stock based on the movements in the options market lately.

PRNewsWire - 3 months ago

REDWOOD CITY, Calif., Sept. 29, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization ...

PRNewsWire - 4 months ago

REDWOOD CITY, Calif., Sept. 14, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.

PRNewsWire - 5 months ago

REDWOOD CITY, Calif., Aug. 19, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.

Seeking Alpha - 5 months ago

ACRX Shareholders had a lot to digest during the past three months, including capital raise, cancelled and new marketing agreements, and the exit from the Tetraphase bidding war.

Zacks Investment Research - 5 months ago

AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 5 months ago

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 42.86% and -25.03%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for th...

PRNewsWire - 5 months ago

REDWOOD CITY, Calif., Aug. 10, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.

PRNewsWire - 5 months ago

REDWOOD CITY, Calif., Aug. 3, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.

Zacks Investment Research - 5 months ago

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: BDSI, BNFT, CLRB, LNT
Zacks Investment Research - 5 months ago

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 7 months ago

REDWOOD CITY, Calif., June 3, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of ...

PRNewsWire - 7 months ago

REDWOOD CITY, Calif., June 1, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovativ...

Seeking Alpha - 7 months ago

AcelRx Pharmaceuticals: Finally Light At The End Of The Tunnel

Seeking Alpha - 8 months ago

AcelRx Pharmaceuticals: Lean Back And Watch The Rocket Launch

Seeking Alpha - 8 months ago

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -33.33% and -85.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for ...

Zacks Investment Research - 8 months ago

AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research - 8 months ago

AcelRx Pharmaceuticals (ACRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 9 months ago

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: AVGR, GNCA, GOSS, VFF
Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor in AcelRx Pharmaceuticals.

Zacks Investment Research - 9 months ago

After the Dow sees a quarter as ugly as this year's first quarter, the 124-year old index on average returns 11.8% in the following quarter. There is similar positive trend for the S&P 500 as ...

Other stocks mentioned: BBW, BCRX, CACI, EVR
Seeking Alpha - 9 months ago

Acelrx Pharmaceuticals: A New Chapter

Seeking Alpha - 10 months ago

AcelRx Acquiring Tetraphase, And Other News: The Good, Bad And Ugly Of Biopharma

Seeking Alpha - 10 months ago

AcelRx Pharmaceuticals, Inc.'s (ACRX) CEO Vince Angotti on Q4 2019 Results - Earnings Call Transcript

Benzinga - 10 months ago

AcelRx Pharmaceuticals (NASDAQ:ACRX) reported Q4 results. Quarterly Results Earnings per share increased 100% over the past year to ($0.18), which beat the estimate of ($0.20).

Zacks Investment Research - 10 months ago

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

During Q4 investors' call, AcelRx (ACRX) is likely to provide an update on the sales uptake of its recently-unveiled product Dsuvia, which is approved for acute pain management.

Zacks Investment Research - 11 months ago

In the latest trading session, AcelRx Pharmaceuticals (ACRX) closed at $1.73, marking a -1.14% move from the previous day.

Zacks Investment Research - 1 year ago

In the latest trading session, AcelRx Pharmaceuticals (ACRX) closed at $1.91, marking a -0.78% move from the previous day.

Zacks Investment Research - 1 year ago

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: BKH, DNKN, DYNT, GTLS
Zacks Investment Research - 1 year ago

AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the ne...

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for January 3rd

Other stocks mentioned: AEIS, HELE, MBT
Seeking Alpha - 1 year ago

The market potential for ACRX is massive and thus the stock at current levels – despite cash management challenges – could provide investors with significant opportunities.

Zacks Investment Research - 1 year ago

AcelRx Pharmaceuticals, Inc. (ACRX) has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research - 1 year ago

AcelRx Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

About ACRX

AcelRx Pharmaceuticals, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx ... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Feb 14, 2011
CEO
Vincent Angotti
Employees
99
Stock Exchange
NASDAQ
Ticker Symbol
ACRX
Full Company Profile

Financial Performance

In 2019, ACRX's revenue was $2.29 million, an increase of 6.42% compared to the previous year's $2.15 million. Losses were -$53.24 million, 12.9% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ACRX stock is "Buy." The 12-month stock price forecast is 5.46, which is an increase of 185.86% from the latest price.

Price Target
$5.46
(185.86% upside)
Analyst Consensus: Buy